#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Congenital pseudarthrosis Neoplasm Small cell lung cancer limited stage Meningococcal immunisation Skin cancer Neuronal ceroid lipofuscinosis Diffuse large B-cell lymphoma refractory Infection in an immunocompromised host Ductal adenocarcinoma of pancreas Haematological malignancy Oesophageal carcinoma Methylmalonic acidaemia Infantile apnoea Acute myeloid leukaemia refractory Gastrointestinal disorder More trials…

    Learn about Rare Diseases

    Pemphigoid – Treatment Leiomyosarcoma – Trials in Disease Adrenocortical carcinoma Glomerulonephritis membranous – Diagnostics Cystic fibrosis lung – Life with Disease Mucopolysaccharidosis III – Trials in Disease Loeys-Dietz syndrome – Life with Disease Toxic epidermal necrolysis – Trials in Disease Pleomorphic leiomyosarcoma – Life with Disease Angiosarcoma non-metastatic – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Amg 193 BMS-986365 Pirfenidone Cefuroxime Axetil Sapablursen BI 456906 Secukinumab Teprotumumab Pevonedistat Chloropyramine Hydrochloride Quc398 Nalbuphine Hydrochloride Ruxotemitide TUB-030 Mezigdomide Damoctocog Alfa Pegol X-396 Art0380 Mesilate Fluorouracil Sodium Valproate Semisodium More therapies…

    Learn about Your Condition

    Endometrial cancer stage II Pain Embolic stroke Diabetic foot Dyslipidaemia Ocular myasthenia Genital infection female Colon cancer metastatic C3 glomerulopathy Non-obstructive cardiomyopathy Drug eruption Eczema Erythema multiforme Pertussis Narcolepsy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Oscar Lambret

Centre Oscar Lambret

3 Rue Frederic Combemale, Lille, 59000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Durvalumab with Chemotherapy and Radiotherapy for Patients with Unresectable Esophageal Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Oesophageal carcinoma
    Investigated Drugs:
    • Durvalumab
    • Fluorouracil
    • Folinic Acid
    France

  • Study of MK-2870 for Patients with Advanced or Metastatic Stomach Cancer, Comparing Its Effects to a Drug Combination

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Buclizine Hydrochloride
    • Codeine Phosphate
    • Docetaxel
    Belgium Denmark France Germany Italy Poland +1

  • Study of Dazostinag and Pembrolizumab for Adults with Advanced or Metastatic Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Dazostinag
    Austria Belgium France Poland

  • Study on Reducing Hormone Therapy Duration with Exemestane, Letrozole, and Anastrozole in Post-Menopausal Women with Low-Risk Hormone-Sensitive Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Anastrozole
    • Exemestane
    • Letrozole
    France

  • Study on Eye Health During Treatment with Mirvetuximab Soravtansine, Brimonidine Tartrate, and Prednisolone Acetate for Patients with Recurrent Ovarian Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • Brimonidine Tartrate
    • Mirvetuximab Soravtansine
    • Prednisolone Acetate
    Belgium France Ireland Spain

  • Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer After Trastuzumab Treatment

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Paclitaxel
    • Ramucirumab
    • Trastuzumab Deruxtecan
    Belgium France Germany Hungary Ireland Italy +4

  • Study on Infertility Risk from Chemotherapy in Young Breast Cancer Patients Using Follitropin Beta and Follitropin Alfa for Egg/Embryo Preservation

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer female
    Investigated Drugs:
    • Follitropin Alfa
    France

  • Study of inavolisib, palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Fulvestrant
    • Inavolisib
    • Palbociclib
    Belgium France Germany Greece Hungary Italy +3

  • Study on Chemotherapy and Pelvic Reirradiation for Patients with Recurrent Rectal Cancer Using Irinotecan, Levoleucovorin, Fluorouracil, Oxaliplatin, and Capecitabine

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Capecitabine
    • Fluorouracil
    • Irinotecan Hydrochloride Trihydrate
    France

  • Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • Trastuzumab Deruxtecan
    • Trastuzumab Emtansine
    Belgium Czechia Denmark France Germany Greece +7
Previous Page
1 … 21 22 23 24 25 26
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!